Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDL NASDAQ:KYNB NASDAQ:PEPG NASDAQ:PMN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.05$1.20$0.88▼$1.71$121.01M0.74321,665 shs412,200 shsKYNBKyntra Bio$7.63$7.00$5.37▼$12.60$30.89M0.9635,571 shs4,970 shsPEPGPepGen$1.76$1.61$1.01▼$7.80$121.74M1.88580,892 shs293,157 shsPMNPromis Neurosciences$13.35$10.71$6.27▼$39.75$119.72M-0.2332,156 shs44,952 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics0.00%+0.96%-8.70%-25.53%-24.46%KYNBKyntra Bio0.00%+4.16%+12.04%+8.84%+762,999,900.00%PEPGPepGen0.00%+3.53%+18.92%+1.73%+45.45%PMNPromis Neurosciences0.00%+26.78%+37.20%+6.71%+19.20%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.05$1.20$0.88▼$1.71$121.01M0.74321,665 shs412,200 shsKYNBKyntra Bio$7.63$7.00$5.37▼$12.60$30.89M0.9635,571 shs4,970 shsPEPGPepGen$1.76$1.61$1.01▼$7.80$121.74M1.88580,892 shs293,157 shsPMNPromis Neurosciences$13.35$10.71$6.27▼$39.75$119.72M-0.2332,156 shs44,952 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics0.00%+0.96%-8.70%-25.53%-24.46%KYNBKyntra Bio0.00%+4.16%+12.04%+8.84%+762,999,900.00%PEPGPepGen0.00%+3.53%+18.92%+1.73%+45.45%PMNPromis Neurosciences0.00%+26.78%+37.20%+6.71%+19.20%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDLCardiol Therapeutics 2.33Hold$8.50709.52% UpsideKYNBKyntra Bio 2.50Moderate Buy$30.00293.18% UpsidePEPGPepGen 2.71Moderate Buy$11.50553.41% UpsidePMNPromis Neurosciences 2.67Moderate Buy$26.5098.50% UpsideCurrent Analyst Ratings BreakdownLatest KYNB, PEPG, CRDL, and PMN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2026PMNPromis Neurosciences Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight6/24/2026CRDLCardiol Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/24/2026PMNPromis Neurosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.006/16/2026KYNBKyntra Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)6/16/2026PEPGPepGen Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$11.006/11/2026PMNPromis Neurosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/9/2026KYNBKyntra Bio Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.006/9/2026PMNPromis Neurosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/8/2026PMNPromis Neurosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.006/2/2026PEPGPepGen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/21/2026PEPGPepGen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDLCardiol TherapeuticsN/AN/AN/AN/A$0.11 per shareN/AKYNBKyntra Bio$6.44M4.80N/AN/A($4.20) per share-1.82PEPGPepGenN/AN/AN/AN/A$2.14 per shareN/APMNPromis NeurosciencesN/AN/AN/AN/A($0.58) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDLCardiol Therapeutics-$24.20M-$0.28N/AN/AN/AN/A-229.43%-165.60%8/13/2026 (Estimated)KYNBKyntra Bio$183.45M$40.460.19N/AN/A2,199.13%N/A-36.71%N/APEPGPepGen-$89.65M-$1.75N/AN/AN/AN/A-59.89%-49.62%8/6/2026 (Estimated)PMNPromis Neurosciences-$39.72M-$14.51N/AN/AN/AN/A-237.99%-151.04%8/12/2026 (Estimated)Latest KYNB, PEPG, CRDL, and PMN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026PEPGPepGen-$0.31-$0.26+$0.05-$0.26N/AN/A5/12/2026Q1 2026PMNPromis Neurosciences-$1.06-$1.26-$0.20-$1.26N/AN/A5/11/2026Q1 2026CRDLCardiol Therapeutics-$0.07-$0.07N/A-$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRDLCardiol TherapeuticsN/AN/AN/AN/AN/AKYNBKyntra BioN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/APMNPromis NeurosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDLCardiol TherapeuticsN/A4.394.39KYNBKyntra BioN/A3.613.48PEPGPepGenN/A14.9814.98PMNPromis NeurosciencesN/A9.929.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDLCardiol Therapeutics12.49%KYNBKyntra Bio72.71%PEPGPepGen58.01%PMNPromis Neurosciences50.13%Insider OwnershipCompanyInsider OwnershipCRDLCardiol Therapeutics5.25%KYNBKyntra Bio4.15%PEPGPepGen1.30%PMNPromis Neurosciences1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDLCardiol Therapeutics20115.25 million109.20 millionNot OptionableKYNBKyntra Bio5704.05 million3.88 millionN/APEPGPepGen3069.17 million68.27 millionNot OptionablePMNPromis Neurosciences58.97 million8.83 millionNot OptionableKYNB, PEPG, CRDL, and PMN HeadlinesRecent News About These CompaniesAnalysts Offer Insights on Healthcare Companies: ProMIS Neurosciences (PMN) and Icon (ICLR)July 1, 2026 | theglobeandmail.comWall Street Analysts See a 230.23% Upside in Promis Neurosciences (PMN): Can the Stock Really Move This High?June 30, 2026 | zacks.comAll You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to BuyJune 12, 2026 | zacks.comWall Street Analysts Think Promis Neurosciences (PMN) Could Surge 231.78%: Read This Before Placing a BetJune 12, 2026 | zacks.comWhy ProMIS Neurosciences, Inc.’s (PMN) Stock Is Down 6.72%June 11, 2026 | aaii.comAProMIS Neurosciences to Participate in Upcoming Conferences in JuneMay 28, 2026 | globenewswire.comProMIS Neurosciences (PMN) Receives a Buy from GuggenheimMay 20, 2026 | theglobeandmail.comProMIS Neurosciences Inc.: ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate HighlightsMay 12, 2026 | finanznachrichten.deProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate HighlightsMay 12, 2026 | globenewswire.comInsider Buying: Promis Neurosciences (NASDAQ:PMN) Director Buys 4,000 Shares of StockApril 24, 2026 | insidertrades.comProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor ConferenceApril 13, 2026 | newsfilecorp.comNProMIS Neurosciences (PMN) price target decreased by 57.76% to 35.06March 28, 2026 | msn.comProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate HighlightsMarch 25, 2026 | finanznachrichten.deProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate HighlightsMarch 25, 2026 | globenewswire.comProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™)March 18, 2026 | globenewswire.comAlly Bridge Group NY LLC Increases Holdings in Promis Neurosciences $PMNMarch 15, 2026 | defenseworld.netDInsider Buying: Promis Neurosciences (NASDAQ:PMN) Director Buys 1,000 Shares of StockMarch 5, 2026 | insidertrades.comPromis Neurosciences (NASDAQ:PMN) Insider Buys $25,005.15 in StockFebruary 24, 2026 | insidertrades.comInsider Buying: Promis Neurosciences (NASDAQ:PMN) Major Shareholder Acquires 700,741 Shares of StockFebruary 6, 2026 | insidertrades.comProMIS Neurosciences Inc.: ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026February 4, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKYNB, PEPG, CRDL, and PMN Company DescriptionsCardiol Therapeutics NASDAQ:CRDL$1.05 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$1.06 +0.01 (+0.95%) As of 07/2/2026 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Kyntra Bio NASDAQ:KYNB$7.63 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$7.65 +0.02 (+0.21%) As of 07/2/2026 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.PepGen NASDAQ:PEPG$1.76 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$1.80 +0.04 (+2.16%) As of 07/2/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.Promis Neurosciences NASDAQ:PMN$13.35 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$13.48 +0.13 (+0.94%) As of 07/2/2026 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
